Gilead Sciences stock last trades at USD 152.43 on September 28, 2026
Published on 09/28/2026 at 21:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock last traded at USD 152.43 on Nasdaq at 19:08 UTC on September 28, 2026, up 0.99 percent from the previous close. The regular trading session was still open at that timestamp.
Trading session
The Nasdaq-listed shares were quoted at USD 152.43, compared with a previous close of USD 150.93. The daily change was USD 1.50, or 0.99 percent.
Lenacapavir access planning
In a September 16, 2026 release, Business Wire reported that Gilead Sciences, Inc. expanded six royalty-free voluntary licensing agreements to include investigational once-yearly lenacapavir for HIV prevention. The agreements cover 120 high-incidence countries and are intended to support manufacturing readiness, technology transfer and future supply planning while the Phase 3 PURPOSE 365 trial is ongoing. The once-yearly formulation has not been approved by any regulatory authority.
In a separate September 15, 2026 release, Business Wire reported that Gilead and the Pan American Health Organization agreed to establish a regional pathway for access to twice-yearly lenacapavir for HIV prevention across PAHO Member States in Latin America and the Caribbean. The arrangement provides an access pathway for 14 countries outside Gilead’s voluntary licensing agreements.
